Evidence map›Paper›PMID 39232206›Full record

ArticleLeukemia2024

Mutational mechanisms in multiply relapsed pediatric acute lymphoblastic leukemia.

Cédric G van der Ham, Lianne C Suurenbroek, Michelle M Kleisman, Željko Antić, Stefan H Lelieveld, Marley Yeong, Liset Westera, Edwin Sonneveld, Peter M Hoogerbrugge, Vincent H J van der Velden and 2 more

Abstract read
In one paragraph

Article in Leukemia, 2024. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 10 papers.

0numbers the graph read from it
0cells of the map it votes in
10citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

10 citing papers in PubMed.

  1. Article
  2. Article
  3. Article
  4. Review
  5. Article
  6. Review
  7. Article
  8. A Thiopurine-like Mutagenic Process Defines TGCT Subtypes.bioRxiv : the preprint server for biology · 2025
    Article
  9. Article
  10. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

12 authors.

Cédric G van der HamPrincess Máxima Center for Pediatric Oncology, Utrecht, The Netherlands.ORCID 0009-0007-0542-6819
Lianne C SuurenbroekPrincess Máxima Center for Pediatric Oncology, Utrecht, The Netherlands.ORCID 0009-0002-0164-0440
Michelle M KleismanPrincess Máxima Center for Pediatric Oncology, Utrecht, The Netherlands.
Željko AntićPrincess Máxima Center for Pediatric Oncology, Utrecht, The Netherlands.ORCID 0000-0001-9398-2637
Stefan H LelieveldPrincess Máxima Center for Pediatric Oncology, Utrecht, The Netherlands.
Marley YeongPrincess Máxima Center for Pediatric Oncology, Utrecht, The Netherlands.
Liset WesteraPrincess Máxima Center for Pediatric Oncology, Utrecht, The Netherlands.
Edwin SonneveldPrincess Máxima Center for Pediatric Oncology, Utrecht, The Netherlands.
Peter M HoogerbruggePrincess Máxima Center for Pediatric Oncology, Utrecht, The Netherlands.
Vincent H J van der VeldenDepartment of Immunology, Erasmus MC, University Medical Center Rotterdam, Rotterdam, The Netherlands.ORCID 0000-0001-9457-3763
Frank N van LeeuwenPrincess Máxima Center for Pediatric Oncology, Utrecht, The Netherlands.ORCID 0000-0003-1107-6513
Roland P KuiperPrincess Máxima Center for Pediatric Oncology, Utrecht, The Netherlands. r.kuiper@prinsesmaximacentrum.nl.ORCID 0000-0003-4928-3809

Funding

KWF Kankerbestrijding (Dutch Cancer Society) 12482
6 · The paper itself

Abstract

Pediatric acute lymphoblastic leukemia (ALL) is marked by low mutational load at initial diagnosis, which increases at relapse. To determine which processes are active in (relapsed) ALL and how they behave during disease progression before and after therapy, we performed whole genome sequencing on 97 tumor samples of 29 multiply relapsed ALL patients. Mutational load increased upon relapse in 28 patients and upon every subsequent relapse in 22 patients. In addition to two clock-like mutational processes, we identified UV-like damage, APOBEC activity, reactive oxygen species, thiopurine-associated damage and an unknown therapy component as drivers of mutagenesis. Mutational processes often affected patients over longer time periods, but could also occur in isolated events, suggesting the requirement of additional triggers. Thiopurine exposure was the most prominent source of new mutations in relapse, affecting over half of the studied patients in first and/or later relapse and causing potential relapse-driving mutations in multiple patients. Our data demonstrate that multiple mutational processes frequently act in parallel as prominent secondary drivers with dynamic activity during ALL development and progression.

Indexed as

MutationPrecursor Cell Lymphoblastic Leukemia-LymphomaAdolescentChildChild, PreschoolFemaleHumansInfantMaleNeoplasm Recurrence, LocalReactive Oxygen SpeciesRecurrenceWhole Genome SequencingReactive Oxygen Species

Identifiers

PMID39232206
PMCPMC11518985

What OpenQuestion holds

Textmetadata
LicenceCC BY-NC-ND
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.